The rare disease diagnostics market was valued at USD 1.92 billion in 2025 and is anticipated to grow from USD 2.44 billion in 2026 to USD 16.88 billion by 2034, registering a CAGR of 27.30% from 2026 to 2034, according to Polaris Market Research. Rare diseases, also called orphan diseases, typically afflict fewer than 1 in 2,000 people, yet collectively they affect millions worldwide. Examples include cystic fibrosis, caused by mutations in the CFTR gene, and Duchenne muscular dystrophy, caused by mutations in the DMD gene. North America was the largest market in 2025.

Segment Landscape

Polaris Market Research segments the rare disease diagnostics market by disease type, product type, sample type, technology, test, age group, trait type, end user, and region. The competitive landscape is described as fragmented, with companies leveraging research and development, diverse product offerings, and global presence, and pursuing collaborations with other companies and research institutions.

The segmentation also covers sample type (blood and buccal swab), test type (genetic, general lab, and imaging), age group (adult and children), and trait type (inherited and acquired), and technologies including array technology, PCR-based testing, FISH, Sanger sequencing, and karyotyping.

Kits and Reagents Lead Product Demand

Kits and reagents dominated by product type with a 48.6% share in 2025 and are expected to keep their position. They are instrumental in rapidly isolating novel disease-causing genes and improving diagnostic accuracy, and they are part of comprehensive options for biochemical and genetic testing, including enzyme testing, biomarker testing, and genetic confirmation through full gene sequencing. Instruments and software complete the product type view. Research laboratories and CROs contribute to the understanding, diagnosis, and treatment of these often-overlooked conditions.

End Users and Disease Areas

Research laboratories and contract research organizations held a 43.2% share in 2025, offering specialized expertise and infrastructure for comprehensive genetic analyses, bioinformatics, and molecular diagnostics. Diagnostic laboratories are also growing substantially as sequencing becomes more accessible, accurate, and cost-effective, and hospitals and clinics complete the end-user group.

By disease area, hematology and oncology led with a 24.7% share in 2025. Rare blood disorders such as hemophagocytic lymphohistiocytosis and Castleman disease are complex because of low incidence, limited research, and often asymptomatic presentation.

The diagnostic process for rare blood disorders and cancers is inherently similar to that for common ones, but low incidence and limited research make it harder. North America's 41.8% share in 2025 is attributed to key players and increasing investment in diagnostic technologies.

Applications from Newborn Screening to Drug Development

The report lists several common applications: rare genetic disorder diagnosis, neurological disorder diagnosis, rare cancer diagnostics, family genetic counseling, and clinical research and drug development, which identifies eligible patients and biomarkers for trials. Newborn screening detects rare congenital disorders early to enable timely intervention, and rising investment in newborn screening is part of the market's future outlook alongside rare disease research and personalized healthcare.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/rare-disease-diagnostics-market 

Multi-Omics and AI-Assisted Variant Interpretation

Polaris highlights emerging technologies including multi-omics diagnostics that combine genomic, proteomic, and metabolomic data, AI-assisted variant interpretation and decision support, digital pathology, long-read sequencing for structural variants, and cloud-based genomic data analysis. Within AI, natural language processing extracts insights from clinical records, AI correlates symptoms with genetic information, and automated genome analysis reduces diagnostic turnaround time.

Recent activity reflects these trends. In June 2026, Sanofi announced the India launch of AccelRare, an AI-enabled digital pre-diagnosis tool. In March 2026, MyOme announced a partnership with Natera and introduced Zenith, a premium exome and genome testing solution. In January 2024, Quest Diagnostics partnered with Ultima Genomics to use high-throughput sequencing technology in oncology and other disease fields. In Asia Pacific, the Asia Pacific Alliance of Rare Disease Organisations, established in 2015, promotes collaboration and awareness.

In February 2024, scientists and clinicians at the Mayo Clinic Center for Individualized Medicine advanced diagnosis and treatment of rare diseases using custom-made RNA. Looking ahead, Polaris expects costs to fall and availability of genomic technologies to rise, improving diagnostic accuracy and decreasing diagnostic delays.

Key Players

• 3billion, Inc.
• Agilent Technologies, Inc
• CENTOGENE N.V.
• Hoffmann-La Roche Ltd.
• FDNA™ INC
• GeneDx, LLC
• Illumina, Inc.
• Invitae Corporation
• Novo Nordisk A/S
• Quest Diagnostics

Conclusion

Product, user, and technology trends together explain how the rare disease diagnostics market is evolving. Kits and reagents remain the largest product category, research laboratories and contract research organizations lead end-user demand, and newborn screening highlights the value of early detection. Multi-omics and AI-assisted variant interpretation are expected to shorten diagnostic timelines as they move into routine use. B2B stakeholders should look for partnerships that connect laboratory capacity with advanced analytics.

More Trending Latest Reports By Polaris Market Research:

Fishing Reels Market

Surgical Blade Market

Book Binding Adhesives Market

Freeze Drying Equipment Market

Electric Commercial Vehicle Traction Motor Market

Hospital Gowns Market

Hospital Gowns Market

Book Binding Adhesives Market

Smart Home Market